SLN on Nasdaq
Silence Therapeutics plc
British pharmaceutical preparations company, incorporated in the United Kingdom.
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with Trevena Inc, Yarrow Bioscience, Inc. or Quantum Cyber N.V., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
61.5%Gross margin3
-16292.8%Operating margin3
-15851.9%Net margin3
-98.7%Revenue growth, 20253
-142.2%Return on equity3
-$62.3MFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue0¢$215.0K
- Research and development100¢$67.8M
- Income tax0¢$11.0K
Out of $559.0K in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | $559.0K | $43.3M | $31.6M |
| Cost of sales | -$215.0K | -$11.8M | |
| Gross profit | $344.0K | $31.4M | |
| Research and development costs | -$67.8M | -$67.9M | |
| General and administrative expenses | -$22.3M | -$26.9M | |
| Restructuring charges | -$1.3M | $0 | |
| Operating loss | -$91.1M | -$63.3M | |
| Foreign currency (loss)/gain, net | -$8.5M | $646.0K | |
| Other income, net | $3.5M | $4.5M | |
| Benefit from R&D credit | $7.5M | $13.7M | |
| Loss before income tax expense | -$88.6M | -$44.5M | |
| Income tax expense | -$11.0K | -$845.0K | |
| Net Loss | -$88.6M | -$45.3M | |
| Loss per share basic | -$0.63 | -$0.33 | |
| Loss per share diluted | -$0.63 | -$0.33 | |
| Weighted-average shares outstanding basic | 141.7M shares | 138.8M shares | |
| Weighted-average shares outstanding diluted | 141.7M shares | 138.8M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $11.3M | $121.3M | |
| Short-term investments | $73.8M | $26.0M | |
| R&D benefit receivable | $22.0M | $24.4M | |
| Other current assets | $11.5M | $14.7M | |
| Trade receivables | $0 | $972.0K | |
| Total current assets | $118.7M | $187.4M | |
| Property, plant and equipment, net | $1.6M | $1.8M | |
| Operating lease right-of-use asset | $167.0K | $157.0K | |
| Goodwill | $10.6M | $9.4M | $10.0M |
| Intangible assets | $288.0K | $312.0K | |
| Other long-term assets | $127.0K | $3.6M | |
| Total assets | $131.4M | $202.6M | |
| Contract liabilities | -$168.0K | -$306.0K | |
| Trade and other payables | -$13.4M | -$16.4M | |
| Operating lease liabilities, current | -$89.0K | -$117.0K | |
| Total current liabilities | -$13.6M | -$16.8M | |
| Contract liabilities | -$55.5M | -$51.8M | |
| Operating lease liabilities, long-term | -$71.0K | $0 | |
| Total liabilities | -$69.1M | -$68.6M | |
| Ordinary shares - par value �.05 per share; 141,701,848 shares issued at December 31, 2025 (2024: 141,674,074) | -$10.3M | -$10.3M | |
| Additional paid-in capital | -$617.6M | -$609.6M | |
| Accumulated deficit | $562.6M | $474.0M | |
| Accumulated other comprehensive loss | $3.0M | $11.8M | |
| Total shareholders' equity | -$62.3M | -$134.0M | -$22.0M |
| Total liabilities and shareholders' equity | -$131.4M | -$202.6M | |
| Ordinary shares - par value | 0.05 GBP | 0.05 GBP | |
| Shares issued | 141.7M shares | 141.7M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $11.3M | $121.3M | |
| Short-term investments | $73.8M | $26.0M | |
| R&D benefit receivable | $22.0M | $24.4M | |
| Other current assets | $11.5M | $14.7M | |
| Trade receivables | $0 | $972.0K | |
| Total current assets | $118.7M | $187.4M | |
| Property, plant and equipment, net | $1.6M | $1.8M | |
| Operating lease right-of-use asset | $167.0K | $157.0K | |
| Goodwill | $10.6M | $9.4M | $10.0M |
| Intangible assets | $288.0K | $312.0K | |
| Other long-term assets | $127.0K | $3.6M | |
| Total assets | $131.4M | $202.6M | |
| Contract liabilities | -$168.0K | -$306.0K | |
| Trade and other payables | -$13.4M | -$16.4M | |
| Operating lease liabilities, current | -$89.0K | -$117.0K | |
| Total current liabilities | -$13.6M | -$16.8M | |
| Contract liabilities | -$55.5M | -$51.8M | |
| Operating lease liabilities, long-term | -$71.0K | $0 | |
| Total liabilities | -$69.1M | -$68.6M | |
| Ordinary shares - par value �.05 per share; 141,701,848 shares issued at December 31, 2025 (2024: 141,674,074) | -$10.3M | -$10.3M | |
| Additional paid-in capital | -$617.6M | -$609.6M | |
| Accumulated deficit | $562.6M | $474.0M | |
| Accumulated other comprehensive loss | $3.0M | $11.8M | |
| Total shareholders' equity | -$62.3M | -$134.0M | -$22.0M |
| Total liabilities and shareholders' equity | -$131.4M | -$202.6M | |
| Ordinary shares - par value | 0.05 GBP | 0.05 GBP | |
| Shares issued | 141.7M shares | 141.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss after tax | -$88.6M | -$45.3M |
| Depreciation expense | $312.0K | $336.0K |
| Amortization expense | $243.0K | $257.0K |
| Share-based compensation expense | $8.1M | $16.3M |
| Net foreign exchange impacts | $11.0M | -$2.6M |
| Other income, net | -$3.5M | -$4.5M |
| Income tax expense | $11.0K | $845.0K |
| Decrease/(increase) in trade receivables | $1.0M | -$904.0K |
| Decrease/(increase) in other current assets | $6.0M | -$1.3M |
| Decrease/(increase) in R&D benefit receivable | $4.0M | -$2.3M |
| Decrease in other long-term assets | $3.7M | |
| (Decrease)/increase in trade and other payables | -$4.1M | $499.0K |
| Decrease in contract liabilities | -$334.0K | -$28.8M |
| Decrease in operating lease liabilities | -$168.0K | -$165.0K |
| Net cash used in operating activities | -$62.3M | -$67.6M |
| Redemption of term deposits | $118.5M | $117.4M |
| Purchase of term deposits | -$166.4M | -$139.2M |
| Purchase of property, plant and equipment | -$55.0K | -$211.0K |
| Net cash used in investing activities | -$48.0M | -$22.0M |
| Proceeds from issue of ordinary shares | $15.0K | $142.1M |
| Net cash provided by financing activities | $15.0K | $142.1M |
| (Decrease)/increase in cash and cash equivalents | -$110.2M | $52.5M |
| Effect of exchange rate fluctuations on cash and cash equivalents held | $195.0K | $60.0K |
| Income Tax Paid net of refunds | -$637.0K | -$433.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Silence Therapeutics plc, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
- Chief executive officerCraig A. Tooman Jan 2, 2025 to Jan 6, 202510
- PresidentCraig A. Tooman Jan 2, 2025 to Jan 6, 202510
- Chief financial officerRhonda Lynette Hellums Jan 2, 2025 to now11
Board members and other officers (9)
- EVP and Chief R&D OfficerSteven J. Romano Jan 2, 2025 to now12
- Interim PEOIain Ross Dec 22, 2025 to now13
- Board memberRhonda Lynette Hellums Jan 6, 2026 to now14
- Board memberCraig A. Tooman Jan 2, 2025 to Jan 6, 202510
- Board memberDavid Lemus Jan 2, 2025 to now15
- Board memberIain Ross Jan 2, 2025 to now16
- Board memberJames Ede-Golightly Jan 2, 2025 to now17
- Board memberMichael H. Davidson Jan 2, 2025 to Jan 6, 202518
- Board memberTimothy McInerney May 20, 2025 to now19
Timeline
- Jan 2, 2025New chief executive Craig A. Tooman becomes CEO10
Filings
205 filings to the SEC since October 2021: 6 annual reports, 5 quarterly reports, 22 major events, 52 insider forms, 35 large holders, 85 other. The latest 20:
- Oct 13, 2026SCHEDULE 13G/A EDGAR
- Oct 13, 2026SCHEDULE 13G EDGAR
- Aug 13, 2026SCHEDULE 13G/A EDGAR
- Aug 13, 2026SCHEDULE 13D/A EDGAR
- Aug 13, 20264 OWNERSHIP DOCUMENT EDGAR
- Aug 12, 20268-K EDGAR
- Aug 12, 2026424B5 EDGAR
- Aug 11, 2026S-3MEF EDGAR
- Aug 10, 2026424B5 EDGAR
- Aug 10, 20268-K EDGAR
- Aug 10, 202610-Q EDGAR
- Aug 10, 20268-K EDGAR
- Jul 16, 20268-K/A EDGAR
- Jul 8, 2026SCHEDULE 13D/A EDGAR
- Jul 7, 20264 OWNERSHIP DOCUMENT EDGAR
- Jun 23, 20268-K EDGAR
- Jun 16, 20268-K EDGAR
- Jun 11, 20268-K EDGAR
- May 27, 2026EFFECT EDGAR
- May 27, 2026424B5 EDGAR
The 205 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 35 such filings since October 2021, the latest 10:
- Oct 13, 2026SCHEDULE 13G/A
- Oct 13, 2026SCHEDULE 13G
- Aug 13, 2026SCHEDULE 13G/A
- Aug 13, 2026SCHEDULE 13D/A
- Jul 8, 2026SCHEDULE 13D/A
- Feb 9, 2026SCHEDULE 13G/A
- Jun 25, 2025SCHEDULE 13D/A
- May 15, 2025SCHEDULE 13G/A
- May 8, 2025SCHEDULE 13D/A
- Apr 24, 2025SCHEDULE 13D/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 72. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Siren, L.L.C. | 3,311,438 | $36.4M | 0.7% | +400,000 |
| TCG Crossover Management, LLC | 3,033,560 | $33.3M | 0.8% | No change |
| Nantahala Capital Management, LLC | 2,693,462 | $29.6M | 0.9% | +546,731 |
| Redmile Group, LLC | 2,164,777 | $23.8M | 1.6% | No change |
| Citadel Advisors LLC | 1,329,625 | $14.6M | 0.0% | +94,818 |
| Nextech Invest Ltd. | 952,400 | $10.5M | 0.5% | No change |
| Millennium Management LLC | 909,279 | $10.0M | 0.0% | −164,912 |
| Tetragon Partners GP Ltd | 764,256 | $8.4M | 1.4% | +134,095 |
| Soleus Capital Management, L.P. | 630,000 | $6.9M | 0.2% | New |
| Balyasny Asset Management L.P. | 610,980 | $6.7M | 0.0% | New |
| 5AM Venture Management, LLC | 476,200 | $5.2M | 1.8% | No change |
| Great Point Partners LLC | 450,000 | $4.9M | 1.2% | −570,489 |
| Morgan Stanley | 403,172 | $4.4M | 0.0% | +337,686 |
| Ameriprise Financial Inc | 370,052 | $4.1M | 0.0% | New |
| Jane Street Group, LLC | 369,151 | $4.1M | 0.0% | +268,224 |
| ADAR1 Capital Management, LLC | 338,373 | $3.7M | 0.2% | +166,216 |
| SummitTX Capital, L.P. | 326,648 | $3.6M | 0.1% | New |
| Schonfeld Strategic Advisors LLC | 269,348 | $3.0M | 0.0% | New |
| UBS Group AG | 243,152 | $2.7M | 0.0% | −3,785 |
| Ishara Investments LP | 55,350 | $2.4M | 1.8% | −85,150 |
| BlackRock, Inc. | 219,917 | $2.4M | 0.0% | +15,140 |
| Bank Of Montreal /can/ | 201,734 | $2.2M | 0.0% | −1,167 |
| Boothbay Fund Management, LLC | 198,347 | $2.2M | 0.0% | −10,741 |
| Propel Bio Management, LLC | 191,733 | $2.1M | 1.1% | New |
| Susquehanna International Group, Llp | 184,519 | $2.0M | 0.0% | +69,238 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13SEC EDGARIain Ross, Interim PEO
- 14SEC EDGARRhonda Lynette Hellums, Board member
- 15SEC EDGARDavid Lemus, Board member
- 16SEC EDGARIain Ross, Board member
- 17SEC EDGARJames Ede-Golightly, Board member
- 18SEC EDGARMichael H. Davidson, Board member
- 19SEC EDGARTimothy McInerney, Board member